India Bats For AI-Driven Gene Sequencing to Power Personalised Medical Prescriptions The GARBH-Ini programme is using AI-driven ultrasound image analysis and genomics tools to identify 66 genetic markers linked to preterm birth risk.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
India is set to transition toward personalised medical prescriptions and predictive medicine, courtesy AI.
In the backdrop of the ongoing AI Impact Summit, Union Minister for Science & Technology Union Minister for Science & Technology Dr. Jitendra Singh said that AI-driven gene sequencing, under the Department of Biotechnology (DBT), will help the transition.
Singh also said large-scale genome sequencing initiatives supported by DBT are already AI-enabled, and future medical prescriptions will increasingly be based on individual genetic profiles analysed through AI-facilitated platforms.
"Our gene sequencing work is AI-driven. Tomorrow, when we move toward personalised prescriptions, they will be based on our gene studies facilitated by Artificial Intelligence," Dr. Jitendra Singh said.
The minister also highlighted DBT's genomics ecosystem could help India's positioning beyond conventional treatment models toward precision healthcare driven by data and computational biology.
The minister also announced that the DBT along with Biotechnology Industry Research Assistance Council (BIRAC) will set up "Bio-AI Mulankur" hubs this year. These integrated, closed-loop research platforms will function as hubs, unifying AI-based predictions, laboratory validation, and data analytics within a single framework.
ALSO READ: Global Tech Leaders Eye India as USD 67.5 Bn AI Investment Looms
According to the ministry, these hubs will focus on genomics diagnostics, biomolecular design, synthetic biology and Ayurveda-based research. The minister added that AI will be institutionalized as a foundational scientific engine within biotechnology, moving beyond its current role as a supplementary analytical tool. This shift aligns with the BioE3 policy's objectives: to strengthen high-performance biomanufacturing for the purpose of driving economic growth, ensuring environmental sustainability, and generating employment.
The minister also noted the use cases of AI in the biotechnology sector. He said that the Indian Tuberculosis Genomic Surveillance Consortium (InTGS), supported by DBT, is using AI to catalogue drug-resistance mutations in Mycobacterium tuberculosis. Similarly, the GARBH-Ini programme is using AI-driven ultrasound image analysis and genomics tools to identify 66 genetic markers linked to preterm birth risk.
ALSO READ: India Joins US-led 'Pax Silica' AI Supply Chain Alliance
India's bio-economy is estimated to grow to reach USD 300 billion by 2030. According to the ministry, India is ranked 12th in the world in biotech, 3rd in Asia-pacific, and has the 3rd largest startups ecosystem globally; and the largest vaccine manufacturer.
On DBT-BIRAC Mulankars, the government said (as of December 2025) as many as 21 proposals have been recommended for funding (Academia proposals: 6 and Industry / Industry-Academia proposals: 15) for setting up of Biofoundries and Biomanufacturing Hubs. These Bioenablers are expected to augment research, innovation and scale up across these sectors, Earlier, DBT IndiaA signed an MoU in August 2025 for collaboration in biotechnology and artificial intelligence.
